Literature DB >> 7521864

Analysis of the probability and risk of cause-specific failure.

R J Caplan1, T F Pajak, J D Cox.   

Abstract

PURPOSE: Kaplan-Meier curves are frequently misused in the analysis of nonsurvival endpoints, such as time to local failure or time to late complications. More appropriate analyses are available and described. METHODS AND MATERIALS: Cumulative incidence is an unbiased estimate of probability of cause-specific failure. Cumulative conditional probability of cause-specific failure reflects risk to patients remaining at risk. Hazard rates also measure risk.
RESULTS: Kaplan-Meier curves overestimate the probability of late complications when there is a high mortality rate. Cumulative incidence and cumulative conditional probability accurately give the probability and risk of cause-specific failure.
CONCLUSION: Kaplan-Meier analysis of cause-specific failure should be avoided because of its misinterpretation as an estimate of probability, in favor of appropriate methods.

Entities:  

Mesh:

Year:  1994        PMID: 7521864     DOI: 10.1016/0360-3016(94)90416-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  The use and interpretation of competing risks regression models.

Authors:  James J Dignam; Qiang Zhang; Masha Kocherginsky
Journal:  Clin Cancer Res       Date:  2012-01-26       Impact factor: 12.531

2.  All-trans-retinoic acid: a phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma.

Authors:  S Phuphanich; C Scott; A J Fischbach; C Langer; W K Yung
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

3.  A phase I/II study of altered fractionated IMRT alone for intermediate T-stage oropharyngeal carcinoma.

Authors:  G Brandon Gunn; Eugene J Endres; Brent Parker; Maria Pia Sormani; Giuseppe Sanguineti
Journal:  Strahlenther Onkol       Date:  2010-08-30       Impact factor: 3.621

4.  Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease.

Authors:  Masayuki Yamanouchi; Jan Skupien; Monika A Niewczas; Adam M Smiles; Alessandro Doria; Robert C Stanton; Andrzej T Galecki; Kevin L Duffin; Nick Pullen; Matthew D Breyer; Joseph V Bonventre; James H Warram; Andrzej S Krolewski
Journal:  Kidney Int       Date:  2017-04-07       Impact factor: 10.612

5.  Long term visual outcome of radiated uveal melanomas in eyes eligible for randomisation to enucleation versus brachytherapy.

Authors:  D H Char; S Kroll; J M Quivey; J Castro
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

6.  Choice and interpretation of statistical tests used when competing risks are present.

Authors:  James J Dignam; Maria N Kocherginsky
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

7.  Cumulative incidence for wait-list death in relation to length of queue for coronary-artery bypass grafting: a cohort study.

Authors:  Boris G Sobolev; Lisa Kuramoto; Adrian R Levy; Robert Hayden
Journal:  J Cardiothorac Surg       Date:  2006-08-24       Impact factor: 1.637

Review 8.  Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype.

Authors:  Gillian C Barnett; Catherine M L West; Alison M Dunning; Rebecca M Elliott; Charlotte E Coles; Paul D P Pharoah; Neil G Burnet
Journal:  Nat Rev Cancer       Date:  2009-01-16       Impact factor: 60.716

Review 9.  Clinical trials of interventional oncology-moving from efficacy to outcomes.

Authors:  James M Franklin; Val Gebski; Graeme J Poston; Ricky A Sharma
Journal:  Nat Rev Clin Oncol       Date:  2014-12-09       Impact factor: 66.675

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.